Beam Therapeutics (BEAM) CEO John M. Evans Sells $589K of Stock

Beam Therapeutics Inc. [BEAM] Chief Executive Officer John M. Evans sold 25,000 shares of the biotechnology company on October 15, 2026. According to a Form 4 filing with the SEC, the shares were sold at an average price of $23.57 for a total value of $589,150. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan. Following the sale, the CEO directly owns 1,047,205 shares, which represents a 2.33% cut in his personal holding. The stock closed at $24.73 on the day of the trade.

Inside John M. Evans's Beam Therapeutics Trade

The sale took place as part of a pre-scheduled trading plan adopted by the executive. The transaction involved 25,000 shares, lowering his stake down to 1,047,205 shares. This follows an earlier sale of 50,000 shares by the CEO on June 30, 2026. The shares traded hands at $23.57 each, contributing to a total transaction value of nearly $589,150.

Other Institutional Activity in Beam Therapeutics

Other large funds adjusted their positions in the biotech firm during the middle of the year. Farallon Capital Management LLC grew its holdings by 101,350 shares, ending with 10,236,396 shares worth about $240.2 million. ARK Investment Management, LLC reduced its stake by 1,898,940 shares, or 15.7%, finishing the period with 10,234,862 shares valued at approximately $240.2 million. Arch Venture Management, Llc kept its stake steady at 4,540,132 shares worth $106.6 million with no net change in its share count. Amova Asset Management Americas Inc trimmed its position by 370,716 shares, or 9.7%, leaving it with 3,455,043 shares valued at about $81.1 million. Sumitomo Mitsui Trust Group, Inc. also cut its holdings by 370,716 shares, or 9.7%, to hold 3,455,043 shares worth roughly $81.1 million.

Beam Therapeutics Inc. Stock Down 5.4%

The company recently traded around $23.40, sitting below its 50-day moving average of $26.34 and its 200-day moving average of $28.37. The stock trades well below its 52-week high of $38.26 while holding above its 52-week low of $20.23. Beam Therapeutics carries a market capitalization of roughly $2.42 billion.

Recent Earnings

The company reported trailing-twelve-month revenue of $156.0 million with a net margin of -55.4% and an earnings per share loss of $0.68. The firm's next financial update is slated for November 3, 2026.

Insider Buying and Selling at Beam Therapeutics Inc.

Insiders have made several transactions over recent months, including sales by other officers and institutional holders like Fmr LLC.

Analysts Set New Price Targets

Wall Street firms maintain positive views on the developer of precision genetic medicines. On October 15, 2026, HC Wainwright & Co. reiterated its buy rating on the stock with an $80.00 price target. The stock currently holds a consensus strong buy rating from 13 analysts with a mean price target of $52.15.

About Beam Therapeutics Inc.

Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on building precision genetic medicines for serious diseases. The firm leverages advanced gene editing techniques to target the molecular roots of various disorders. Insiders and institutional funds continue to adjust their holdings as the company advances its clinical pipeline toward upcoming regulatory and developmental milestones.

Bottom Line

Investors will watch for the company's next earnings report on November 3, 2026, for further updates on its clinical programs and financial runway. Regulatory filings will continue to provide visibility into how executives and major shareholders manage their equity stakes.